2019 Executive Sponsors
2019 Associate Sponsors
2019 Supporting & Educational Partners
2019 Media Partners
2019 Supporting & Educational Partners
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.
The Association for Cancer Immunotherapy (CIMT) is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. CIMT has its offices in Mainz, Germany, and is financed by donations, congress fees, industry sponsorships and by public and foundation grants. For more information, visit www.cimt.eu.
Cancer Research Institute is a nonprofit organization dedicated exclusively to the advancement of immunotherapy for cancer. It raises funds and provides research grants to laboratory and clinical scientists who are progressing this field. It also connects patients with cancer immunotherapy clinical trials and with other patients and caregivers considering treatment with immunotherapy. Learn more at www.cancerresearch.org.
Established in 1983, the Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology and NIH-designated Research, Evaluation and Commercialization Hub (REACH).
The Center for Biotechnology serves as an important catalyst in the development of new biomedical technologies and emerging companies in New York State. Through groundbreaking initiatives, the Center supports technology commercialization and company formation by bridging the gap between discovery and commercial success, and by training the next generation of biomedical leaders. The Center for Biotechnology also supports New York’s biotechnology industry by providing access to scientific and business expertise and creating strategic infrastructure that promotes the growth of the life sciences industry in the State. The Center for Biotechnology has contributed to the development of more than a dozen FDA approved products including ReoPro®, Xiaflex®, Oracea®, Cavistat®, V3D®-Colon Virtual Colonoscopy and Exogen® Bone Healing System, among others, as well as supported the formation or development of dozens of emerging bioscience companies. Learn more at www.centerforbiotechnology.org.
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a not-for-profit organization of medical professionals dedicated to improving patient outcomes by advancing the development, science and application of cancer immunotherapy. As the world’s leading member-driven organization dedicated to cancer immunotherapy and tumor immunology, SITC is comprised of nearly 1,000 influential basic and translational scientists, clinicians, health care professionals, government leaders and industry professionals from around the globe. For more information about SITC, please visit www.sitcancer.org.
Solebury Trout is a full-service investor relations and corporate communications firm offering integrated solutions for private and public clients. The company’s deep sector expertise and the firm’s global reach extends through a network of offices in New York, Boston, Stamford and San Francisco, as well as consultants in the U.K., helps clients connect with the audiences who matter most–including investors, analysts, the media, employees and customers. A highly-experienced team of 60 senior professionals has expertise in investor relations, equity research, portfolio management, private equity, investment banking, journalism and corporate communications. Solebury Trout is affiliated with Solebury Capital, the leading equity capital markets advisory firm, and is a subsidiary of The PNC Financial Services Group, Inc. Learn more at www.soleburytrout.com.
2019 Media Partners
Pharmalicensing is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.
Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world.
Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc. Learn more at www.pharmalicensing.com.
STAT is a national publication that delivers fast, deep, and tough-minded journalism about life sciences and the fast-moving business of making medicines. We take you inside academic labs, biotech boardrooms, and political backrooms. With an award-winning newsroom, STAT gives you indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life science industry — and a revolution in human health. These are the stories that matter to us all. Learn more about www.statnews.com.
We enjoy collaborating with the media. If you are interested in becoming a media partner, please contact: firstname.lastname@example.org | 646-350-2580